Search results
Showing 901 to 950 of 8905 results
Evidence-based recommendations on atogepant (Aquipta) for preventing migraine in adults.
Evidence-based recommendations on tisagenlecleucel (Kymriah) for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under.
25 years of NICE and focusing on what matters most to deliver for the future
Home News Podcasts 25 years of NICE and focusing on what matters most to deliver for the future Podcasts 01 May 2024 Listen About this episode
Tumour profiling tests to guide adjuvant chemotherapy decisions in early breast cancer (HTG719)
Evidence-based recommendations on tumour profiling tests (EndoPredict, ICH4+C, MammaPrint, Oncotype DX and Prosigna) to guide adjuvant chemotherapy decisions in early breast cancer.
NICE collaborates with international partner agencies to streamline the confidential marking process
NICE, the Canadian Agency for Drugs and Technologies in Health and the US’s Institute for Clinical and Economic Review changes the way information about health technologies is handled to streamline processes and increase transparency.
Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 (TA971)
Evidence-based recommendations on remdesivir (Veklury) and tixagevimab plus cilgavimab (Evusheld) for treating COVID-19.
Evidence-based recommendations on selinexor (Nexpovio) with dexamethasone for treating relapsed and refractory multiple myeloma after 4 or more treatments in adults.
What are the risk factors for acne vulgaris-related scarring?
Recommendation ID NG198/6 Question What are the risk factors for acne vulgaris-related scarring? Any explanatory notes(if applicable)
What is the effect of dietary interventions or dietary changes on acne?
Recommendation ID NG198/3 Question What is the effect of dietary interventions or dietary changes on acne? Any explanatory notes(if
What is the effectivness of statin treatment in older people?
Recommendation ID NG238//2 Question What is the effectivness of statin treatment in older people? Any explanatory notes(if applicable)
Recommendation ID NG238/1 Question What is the effectiveness of age alone and other routinely available risk factors compared with the
Recommendation ID NG198/4 Question What skin care advice is appropriate for people with acne? Any explanatory notes(if applicable)
What information and support is valued by people with acne vulgaris?
Recommendation ID NG198/9 Question What information and support is valued by people with acne vulgaris? Any explanatory notes(if
What is the effectiveness of hormone-modifying agents in the treatment of acne vulgaris?
Recommendation ID NG198/8 Question What is the effectiveness of hormone-modifying agents in the treatment of acne vulgaris? Any explanatory
Recommendation ID NG238/3 Question What is the effectivness of stains and/or other lipid-lowering treatment in people with type 1 diabetes
Recommendation ID NG198/2 Question What is the most effective first-line treatment option for any severity of acne vulgaris for people
Recommendation ID NG198/5 Question What is the effectiveness of physical treatments (such as light devices) in the treatment of acne vulgaris
Recommendation ID NG198/7 Question What is the effectiveness of chemical peels for the treatment of acne vulgaris or persistent acne vulgaris-related
What is the efficacy of reduced dose oral isotretinoin in the management of acne vulgaris?
Recommendation ID NG198/1 Question What is the efficacy of reduced dose oral isotretinoin in the management of acne vulgaris? Any
Recommendation ID IPG779 Question Middle meningeal artery embolisation for chronic subdural haematomas should be used only in research
Artificial intelligence (AI)-derived software to help clinical decision making in stroke (HTG708)
Evidence-based recommendations on artificial intelligence-derived software to help clinical decision making in stroke.
Evidence-based recommendations on pembrolizumab (Keytruda) for relapsed or refractory classical Hodgkin lymphoma in people 3 years and over.
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma (TA540)
Evidence-based recommendations on pembrolizumab (Keytruda) for treating relapsed or refractory classical Hodgkin lymphoma in adults.
Gefapixant for treating refractory or unexplained chronic cough (terminated appraisal) (TA969)
NICE is unable to make a recommendation on gefapixant (Lyfnua) for treating refractory or unexplained chronic cough in adults. This is because Merck Sharp & Dohme did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA969
170,000 people in England to have further treatment choice for preventing migraine attacks
In final draft guidance published today NICE has recommended atogepant, the first of a new type of oral treatment option for preventing both chronic and episodic migraines, opening the way for up to 170,000 people to choose it on the NHS in England.
NICE is unable to make a recommendation on melphalan flufenamide (Pepaxti) for treating relapsed or refractory multiple myeloma in adults. This is because Oncopeptides did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA968
NICE is unable to make a recommendation on pembrolizumab (Keytruda) with gemcitabine and cisplatin for untreated advanced biliary tract cancer in adults. This is because Merck Sharp & Dohme did not provide an evidence submission. We will review this decision if the company decides to make a submission.
Show all sections
Sections for TA966
Evidence-based recommendations on lymphovenous anastomosis during axillary or inguinal node dissection for preventing secondary lymphoedema in adults. This involves diverting some of the lymphatic vessels around where lymph nodes have been removed to nearby veins.
View recommendations for HTG717Show all sections
Innovative CAR-T therapy recommended to treat an aggressive form of leukaemia.
NICE launches second consultation on genetic testing to guide treatment after a stroke
People could be offered a genetic test in the immediate period after having a stroke to help identify the most suitable treatment to reduce their risk of further strokes.
Cabozantinib with nivolumab for untreated advanced renal cell carcinoma (TA964)
Evidence-based recommendations on cabozantinib (Cabometyx) with nivolumab (Opdivo) for untreated advanced renal cell carcinoma in adults.
This guideline covers care for pregnant women and pregnant people with a twin or triplet pregnancy in addition to routine care during pregnancy and labour. It aims to reduce the risk of complications and improve outcomes.
Home What NICE does Our guidance About technology appraisal guidance Our methods and processes (health technology evaluation manual)...
GaitSmart rehabilitation exercise programme for gait and mobility issues (HTG716)
Evidence-based recommendations on GaitSmart rehabilitation exercise programme for gait and mobility issues in adults.
Evidence-based recommendations on Kurin Lock for blood culture collection.
Epidermal radiotherapy using rhenium-188 paste for non-melanoma skin cancer (HTG714)
Evidence-based recommendations on epidermal radiotherapy using rhenium-188 paste for non-melanoma skin cancer. This involves radioactive paste being spread on foil over the top of the cancer, to destroy the cancer cells.
View recommendations for HTG714Show all sections
NICE is unable to make a recommendation on sebelipase alfa (Kanuma) for treating lysosomal lipase deficiency that is not Wolman disease in adults. The Wolman disease population was evaluated separately in NICE highly specialised technology guidance on sebelipase alfa (HST30). The cost effectiveness of the remaining non-Wolman population has not been demonstrated at this stage.
Show all sections
Sections for TA961
Human alpha1-proteinase inhibitor for treating emphysema (terminated appraisal) (TA965)
NICE is unable to make a recommendation on human alpa1-proteinase inhibitor (Respreeza) for treating emphysema in adults. CSL Behring UK has confirmed that it does not intend to launch the product in England and Wales. The reasons for this decision are primarily related to the company’s inability to offer the product at a price to meet the current threshold of cost effectiveness.
Show all sections
Sections for TA965
Evidence-based recommendations on olaparib (Lynparza) for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy in adults.
Ritlecitinib for treating severe alopecia areata in people 12 years and over (TA958)
Evidence-based recommendations on ritlecitinib (Litfulo) for treating severe alopecia areata in people 12 years and over.
Evidence-based recommendations on daratumumab (Darzalex) for newly diagnosed systemic amyloid light-chain amyloidosis in adults.
NICE is unable to make a recommendation on satralizumab (Enspryng) for preventing relapses in neuromyelitis optica spectrum disorders in adults
Show all sections
Sections for TA960
Summary of the evidence on desflurane for maintenance of anaesthesia
Early value assessment (EVA) guidance on digital health technologies to help manage symptoms of psychosis and prevent relapse in adults and young people.
Gynaecological conditions: rates of endometrial ablation (heavy menstrual bleeding) (IND59)
This indicator covers rates of endometrial ablation. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG78
Gynaecological conditions: rates of hysterectomy (heavy menstrual bleeding) (IND58)
This indicator covers rates of hysterectomy. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG77
This indicator covers the proportion of people with dementia prescribed anti-psychotic medication. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG18
Pregnancy and neonates: mental health at booking appointment (IND63)
This indicator covers proportion of pregnant women who were asked about their mental health at their first booking appointment. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG82
This indicator covers mortality rates directly associated with VTE. It measures outcomes that reflect the quality of care or processes linked by evidence to improved outcomes. This indicator was previously published as CCG80
Ovarian cancer: identifying and managing familial and genetic risk (NG241)
This guideline covers assessing the familial and genetic risk of having a pathogenic variant associated with ovarian cancer in adults.